The severe and caustic nature of alkali chemical burns affecting the eye often leads to permanent ocular injury and resulting vision loss. Treatment options are […]
read moreIn this article, Dr. Paul Karpecki takes a closer look at the various hyaluronic acid (HA)-based products optometrists currently have access to and the future […]
read moreCorneal ulcers are an ocular emergency and a leading cause of blindness globally. The treatment regimen usually requires hourly (or in some cases, even more […]
read moreResponses to three of the four outstanding action items submitted; Response to Fourth action item Expected in the Second Quarter of 2018 with Potential to […]
read moreWALTHAM, Mass., May 16, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies […]
read moreWALTHAM, Mass., May. 11, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies […]
read moreWALTHAM, Mass., April 17, 2018 — EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products […]
read moreWALTHAM, Mass., April 13, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for […]
read moreWALTHAM, Mass., April 11, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for […]
read moreFeedback Provides Clear Path to Resubmission; Expected July 2018 WALTHAM, Mass., April 09, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, […]
read more